Median Technologies Announces New Outstanding Performance for its iBiopsy Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization
iBiopsy's Lung Cancer Screening performance (LCS) for stage 1 lung cancer reaches 93.1% sensitivity at 96.2% specificity. These results are critical for lung cancer characterization at an
Source: finanznachrichten.de